Sygnature Discovery, a world-leading integrated drug discovery provider and non-clinical solutions provider, has announced a scientific collaboration with human induced pluripotent stem cell (iPSC) experts, Axol Bioscience. The collaboration aims to explore the incorporation of human iPSC-derived microglia into high-content imaging in vitro screening workflows. Human iPSC-derived cells are stem cells derived from patient donors […]

The post Sygnature Discovery collaborates with Axol Bioscience to utilize human iPSC-derived microglial cells in high-content imaging drug discovery screening workflows first appeared on World Pharma Today.